AMPHAmphastar Pharmaceuticals, Inc.
Is it safe?
Nothing alarming, nothing pristine: comfortable debt (A) and big price swings.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -74% · now 12% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can AMPH take a bad year?
The deepest fall in AMPH's price history on file is −74%; it is 12% below its high today.
Net debt · as at Q2 2026 · debt less the cash on hand
- Interest cover
- 4.37×
Interest cover · operating profit covers the interest bill, with room to spare
- Annualised volatility
- 47%
Annualised volatility · roughly twice as jumpy as the market
- Worst drawdown on file
- −74%
Worst drawdown on file · −12% today
Details›
- Total debtQ2 2026
- $612M
- Cash and short-term investments
- $290M
- Net debt
- $322M
- Operating profit, trailing twelve months
- $114M
- Debt / equity
- 0.80×
- Annualised volatilitytwo years of daily moves
- 47%
- Worst drawdown on file
- −74%
- Below its 52-week high
- 12%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers, Specialty & Generic
Ranks #4 of 41 by RyuScore